{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:30:54Z","timestamp":1785522654950,"version":"3.56.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40744-026-00859-w","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T14:21:03Z","timestamp":1779546063000},"page":"1075-1089","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Upadacitinib Persistence and Clinical Outcomes Among Canadian Patients with Inflammatory Arthritis from a Patient Support Program: The UPRAISE Study"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1479-5302","authenticated-orcid":false,"given":"Janet E.","family":"Pope","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayeshkumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Saffore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siran","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al","family":"Rasymas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0319-6131","authenticated-orcid":false,"given":"Dalinda","family":"Liazoghli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Ziouzina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"issue":"3","key":"859_CR1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.semarthrit.2016.05.012","volume":"46","author":"LC Coates","year":"2016","unstructured":"Coates LC, FitzGerald O, Helliwell PS, Paul C. Psoriasis, psoriatic arthritis, and rheumatoid arthritis: is all inflammation the same? Semin Arthritis Rheum. 2016;46(3):291\u2013304. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.05.012.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"859_CR2","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.semarthrit.2020.10.010","volume":"51","author":"M Geijer","year":"2021","unstructured":"Geijer M, Alenius GM, Andre L, et al. Health-related quality of life in early psoriatic arthritis compared with early rheumatoid arthritis and a general population. Semin Arthritis Rheum. 2021;51(1):246\u201352. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.10.010.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"859_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.47196\/rar.v31i2.401","volume":"31","author":"G Citera","year":"2020","unstructured":"Citera G, Mysler E, Soriano ER. Treat to persist\", a deepening of the \"treat to target. Rev Argent Reumatol. 2020;31(2):4\u20136. https:\/\/doi.org\/10.47196\/rar.v31i2.401.","journal-title":"Rev Argent Reumatol"},{"issue":"10136","key":"859_CR4","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/s0140-6736(18)30949-8","volume":"391","author":"F Van den Bosch","year":"2018","unstructured":"Van den Bosch F, Coates L. Clinical management of psoriatic arthritis. Lancet. 2018;391(10136):2285\u201394. https:\/\/doi.org\/10.1016\/s0140-6736(18)30949-8.","journal-title":"Lancet"},{"issue":"4","key":"859_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040880","volume":"9","author":"YJ Lin","year":"2020","unstructured":"Lin YJ, Anzaghe M, Schulke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9(4):880. https:\/\/doi.org\/10.3390\/cells9040880.","journal-title":"Cells"},{"key":"859_CR6","unstructured":"AbbVie receives Health Canada approval of RINVOQ\u00ae (upadacitinib), an oral medication for the treatment of adults with moderate-to-severe active rheumatoid arthritis [press release]. 7 January 2020."},{"key":"859_CR7","unstructured":"Health Canada approves AbbVie\u2019s RINVOQ\u00ae (upadacitinib) for the treatment of adults with active psoriatic arthritis [press release]. 7 June 2021."},{"key":"859_CR8","unstructured":"AbbVie Inc. Canadian Product Monograph: RINVOQ\u00ae."},{"key":"859_CR9","unstructured":"Health Canada approves AbbVie's RINVOQ\u00ae (upadacitinib) for the treatment of adults with active ankylosing spondylitis [press release]. 20 July 2022."},{"key":"859_CR10","unstructured":"Health Canada approves AbbVie's RINVOQ\u00ae (upadacitinib) for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) [press release]. 9 May 2023."},{"issue":"3","key":"859_CR11","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/rheumatology\/kez324","volume":"59","author":"J Pope","year":"2020","unstructured":"Pope J, Bessette L, Jones N, et al. Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 years. Rheumatology (Oxford). 2020;59(3):568\u201374. https:\/\/doi.org\/10.1093\/rheumatology\/kez324.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"859_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-020-05278-3","volume":"20","author":"A Bourdin","year":"2020","unstructured":"Bourdin A, Dubois J, Foley RA, Schluep M, Bugnon O, Berger J. Satisfaction and experiences of patients taking fingolimod and involved in a pharmacy-based patient support program in Switzerland\u2014a qualitative study. BMC Health Serv Res. 2020;20(1):425. https:\/\/doi.org\/10.1186\/s12913-020-05278-3.","journal-title":"BMC Health Serv Res"},{"issue":"7","key":"859_CR13","doi-asserted-by":"publisher","first-page":"770","DOI":"10.18553\/jmcp.2019.18443","volume":"25","author":"D Brixner","year":"2019","unstructured":"Brixner D, Rubin DT, Mease P, et al. Patient support program increased medication adherence with lower total health care costs despite increased drug spending. J Manag Care Spec Pharm. 2019;25(7):770\u20139. https:\/\/doi.org\/10.18553\/jmcp.2019.18443.","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"859_CR14","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1007\/s12325-021-01768-w","volume":"38","author":"AM Near","year":"2021","unstructured":"Near AM, Burudpakdee C, Viswanathan S, Kaila S. Effect of a patient support program for idiopathic pulmonary fibrosis patients on medication persistence: a retrospective database analysis. Adv Ther. 2021;38(7):3888\u201399. https:\/\/doi.org\/10.1007\/s12325-021-01768-w.","journal-title":"Adv Ther"},{"key":"859_CR15","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.2147\/PPA.S326498","volume":"15","author":"G Argenziano","year":"2021","unstructured":"Argenziano G, Amerio P, Aragone MG, et al. Assessing the beneficial impact of a patient support program in secukinumab-treated patients with psoriasis in Italy. Patient Prefer Adherence. 2021;15:2551\u201362. https:\/\/doi.org\/10.2147\/PPA.S326498.","journal-title":"Patient Prefer Adherence"},{"key":"859_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2147\/PPA.S77053","volume":"9","author":"C Burudpakdee","year":"2015","unstructured":"Burudpakdee C, Khan ZM, Gala S, Nanavaty M, Kaura S. Impact of patient programs on adherence and persistence in inflammatory and immunologic diseases: a meta-analysis. Patient Prefer Adherence. 2015;9:435\u201348. https:\/\/doi.org\/10.2147\/PPA.S77053.","journal-title":"Patient Prefer Adherence"},{"key":"859_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/PPA.S343949","volume":"16","author":"A Natalicchio","year":"2022","unstructured":"Natalicchio A, Sculco C, Belletti G, Fontanelli M, Galeone C, Bossi AC. Patient-support program in diabetes care during the COVID-19 pandemic: an Italian multicentric experience. Patient Prefer Adherence. 2022;16:113\u201322. https:\/\/doi.org\/10.2147\/PPA.S343949.","journal-title":"Patient Prefer Adherence"},{"key":"859_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1129385","volume":"14","author":"AR Assefi","year":"2023","unstructured":"Assefi AR, Graham S, Crespo ML, et al. Evaluating the TUITEK((R)) patient support program in supporting caregivers of children diagnosed with growth hormone deficiency in Argentina. Front Endocrinol (Lausanne). 2023;14:1129385. https:\/\/doi.org\/10.3389\/fendo.2023.1129385.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"859_CR19","doi-asserted-by":"publisher","first-page":"859","DOI":"10.18553\/jmcp.2017.16272","volume":"23","author":"DT Rubin","year":"2017","unstructured":"Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M. Impact of a patient support program on patient adherence to adalimumab and direct medical costs in Crohn\u2019s disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis. J Manag Care Spec Pharm. 2017;23(8):859\u201367. https:\/\/doi.org\/10.18553\/jmcp.2017.16272.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"859_CR20","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.clinthera.2018.04.017","volume":"40","author":"JK Marshall","year":"2018","unstructured":"Marshall JK, Bessette L, Shear NH, et al. Canada\u2019s study of adherence outcomes in patients receiving adalimumab: 3-year results from the COMPANION study. Clin Ther. 2018;40(6):1024\u201332. https:\/\/doi.org\/10.1016\/j.clinthera.2018.04.017.","journal-title":"Clin Ther"},{"issue":"3","key":"859_CR21","doi-asserted-by":"publisher","first-page":"415 e6","DOI":"10.1016\/j.clinthera.2018.02.001","volume":"40","author":"JK Marshall","year":"2018","unstructured":"Marshall JK, Bessette L, Thorne C, et al. Impact of the adalimumab patient support program\u2019s care coach calls on persistence and adherence in Canada: An observational retrospective cohort study. Clin Ther. 2018;40(3):415 e6-429. https:\/\/doi.org\/10.1016\/j.clinthera.2018.02.001.","journal-title":"Clin Ther"},{"issue":"4","key":"859_CR22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/jcag\/gwy059","volume":"1","author":"N Narula","year":"2018","unstructured":"Narula N, Millson B, Charland K, et al. Impact of adalimumab patient support program\u2019s care coach calls on clinical outcomes in patients with Crohn\u2019s disease in Canada: an observational retrospective cohort study. J Can Assoc Gastroenterol. 2018;1(4):191\u20138. https:\/\/doi.org\/10.1093\/jcag\/gwy059.","journal-title":"J Can Assoc Gastroenterol"},{"issue":"1","key":"859_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40744-018-0109-3","volume":"5","author":"L Bessette","year":"2018","unstructured":"Bessette L, Lebovic G, Millson B, et al. Impact of the adalimumab patient support program on clinical outcomes in ankylosing spondylitis: results from the COMPANION study. Rheumatol Ther. 2018;5(1):75\u201385. https:\/\/doi.org\/10.1007\/s40744-018-0109-3.","journal-title":"Rheumatol Ther"},{"issue":"8","key":"859_CR24","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.18553\/jmcp.2021.20560","volume":"27","author":"AM Fendrick","year":"2021","unstructured":"Fendrick AM, Brixner D, Rubin DT, et al. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit. J Manag Care Spec Pharm. 2021;27(8):1086\u201395. https:\/\/doi.org\/10.18553\/jmcp.2021.20560.","journal-title":"J Manag Care Spec Pharm"},{"key":"859_CR25","unstructured":"U.S. Food and Drug Administration. Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision Making for Drug and Biological Products. Final Guidance, August 2023."},{"key":"859_CR26","unstructured":"European Medicines Agency. Reflection paper on use of real-world data in non interventional studies to generate real-world evidence. April 2025."},{"key":"859_CR27","volume-title":"Quality of Life and pharmacoeconomics in clinical trials","author":"DR Ramey","year":"1996","unstructured":"Ramey DR, Fries JF, Singh G. The Health Assessment Questionnaire 1995-status and review. In: Spilker B, editor. Quality of Life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1996.","edition":"2"},{"issue":"3","key":"859_CR28","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.semarthrit.2018.05.010","volume":"48","author":"P Mease","year":"2018","unstructured":"Mease P, Strand V, Gladman D. Functional impairment measurement in psoriatic arthritis: importance and challenges. Semin Arthritis Rheum. 2018;48(3):436\u201348. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.05.010.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"859_CR29","first-page":"557","volume":"20","author":"GA Wells","year":"1993","unstructured":"Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient\u2019s perspective. J Rheumatol. 1993;20(3):557\u201360.","journal-title":"J Rheumatol"},{"issue":"3","key":"859_CR30","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/art.20048","volume":"50","author":"E Krishnan","year":"2004","unstructured":"Krishnan E, Sokka T, Hakkinen A, Hubert H, Hannonen P. Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum. 2004;50(3):953\u201360. https:\/\/doi.org\/10.1002\/art.20048.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"859_CR31","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.3899\/jrheum.110546","volume":"38","author":"PJ Mease","year":"2011","unstructured":"Mease PJ, Woolley JM, Bitman B, Wang BC, Globe DR, Singh A. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol. 2011;38(11):2461\u20135. https:\/\/doi.org\/10.3899\/jrheum.110546.","journal-title":"J Rheumatol"},{"key":"859_CR32","unstructured":"Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada, Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans, December 2022. (Article 2.4)."},{"issue":"30","key":"859_CR33","doi-asserted-by":"publisher","first-page":"E1000","DOI":"10.1503\/cmaj.221018","volume":"195","author":"S Zeitouny","year":"2023","unstructured":"Zeitouny S, Cheng L, Wong ST, Tadrous M, McGrail K, Law MR. Prevalence and predictors of primary nonadherence to medications prescribed in primary care. CMAJ. 2023;195(30):E1000\u20139. https:\/\/doi.org\/10.1503\/cmaj.221018.","journal-title":"CMAJ"},{"issue":"4","key":"859_CR34","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s11606-010-1253-9","volume":"25","author":"MA Fischer","year":"2010","unstructured":"Fischer MA, Stedman MR, Lii J, et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med. 2010;25(4):284\u201390. https:\/\/doi.org\/10.1007\/s11606-010-1253-9.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"859_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1580-5","volume":"20","author":"HJ Kan","year":"2018","unstructured":"Kan HJ, Dyagilev K, Schulam P, et al. Factors associated with physicians\u2019 prescriptions for rheumatoid arthritis drugs not filled by patients. Arthritis Res Ther. 2018;20(1):79. https:\/\/doi.org\/10.1186\/s13075-018-1580-5.","journal-title":"Arthritis Res Ther"},{"key":"859_CR36","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.2147\/PPA.S215037","volume":"13","author":"D Brixner","year":"2019","unstructured":"Brixner D, Mittal M, Rubin DT, et al. Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population. Patient Prefer Adherence. 2019;13:1545\u201356. https:\/\/doi.org\/10.2147\/PPA.S215037.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"859_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2018-000593","volume":"6","author":"FL Zhou","year":"2018","unstructured":"Zhou FL, Yeaw J, Karkare SU, DeKoven M, Berhanu P, Reid T. Impact of a structured patient support program on adherence and persistence in basal insulin therapy for type 2 diabetes. BMJ Open Diabetes Res Care. 2018;6(1):e000593. https:\/\/doi.org\/10.1136\/bmjdrc-2018-000593.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"10","key":"859_CR38","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1007\/s12325-023-02619-6","volume":"40","author":"M Bergman","year":"2023","unstructured":"Bergman M, Chen N, Thielen R, Zueger P. One-year medication adherence and persistence in rheumatoid arthritis in clinical practice: a retrospective analysis of upadacitinib, adalimumab, baricitinib, and tofacitinib. Adv Ther. 2023;40(10):4493\u2013503. https:\/\/doi.org\/10.1007\/s12325-023-02619-6.","journal-title":"Adv Ther"},{"issue":"1","key":"859_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40744-024-00736-4","volume":"12","author":"P Youssef","year":"2025","unstructured":"Youssef P, Ciciriello S, Tahir T, et al. Real-world persistence and effectiveness of upadacitinib versus other Janus kinase inhibitors and tumor necrosis factor inhibitors in Australian patients with rheumatoid arthritis. Rheumatol Ther. 2025;12(1):173\u2013202. https:\/\/doi.org\/10.1007\/s40744-024-00736-4.","journal-title":"Rheumatol Ther"},{"key":"859_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152314","volume":"64","author":"L Scheepers","year":"2024","unstructured":"Scheepers L, Yang Y, Chen YL, Jones G. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study. Semin Arthritis Rheum. 2024;64:152314. https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152314.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"859_CR41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40744-017-0061-7","volume":"4","author":"F Van den Bosch","year":"2017","unstructured":"Van den Bosch F, Ostor AJK, Wassenberg S, et al. Impact of participation in the adalimumab (Humira) patient support program on rheumatoid arthritis treatment course: results from the PASSION study. Rheumatol Ther. 2017;4(1):85\u201396. https:\/\/doi.org\/10.1007\/s40744-017-0061-7.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"859_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-005566","volume":"11","author":"I van Es","year":"2025","unstructured":"van Es I, Vriezekolk JE, den Broeder N, et al. Cycle versus swap strategy after TNFi discontinuation in psoriatic arthritis and axial spondyloarthritis: a quasi-experimental study. RMD Open. 2025;11(2):e005566. https:\/\/doi.org\/10.1136\/rmdopen-2025-005566.","journal-title":"RMD Open"},{"issue":"8","key":"859_CR43","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s12325-012-0037-5","volume":"29","author":"M Bonafede","year":"2012","unstructured":"Bonafede M, Fox KM, Watson C, Princic N, Gandra SR. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther. 2012;29(8):664\u201374. https:\/\/doi.org\/10.1007\/s12325-012-0037-5.","journal-title":"Adv Ther"},{"issue":"9","key":"859_CR44","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1136\/ard-2023-225271","volume":"83","author":"B Hernandez-Cruz","year":"2024","unstructured":"Hernandez-Cruz B, Otero-Varela L, Freire-Gonzalez M, et al. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry. Ann Rheum Dis. 2024;83(9):1189\u201399. https:\/\/doi.org\/10.1136\/ard-2023-225271.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"859_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02417-x","volume":"23","author":"A Haddad","year":"2021","unstructured":"Haddad A, Gazitt T, Feldhamer I, et al. Treatment persistence of biologics among patients with psoriatic arthritis. Arthritis Res Ther. 2021;23(1):44. https:\/\/doi.org\/10.1186\/s13075-021-02417-x.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"859_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002681","volume":"8","author":"L Pina Vegas","year":"2022","unstructured":"Pina Vegas L, Hoisnard L, Bastard L, Sbidian E, Claudepierre P. Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS). RMD Open. 2022;8(2):e002681. https:\/\/doi.org\/10.1136\/rmdopen-2022-002681.","journal-title":"RMD Open"},{"issue":"15","key":"859_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13154480","volume":"13","author":"V Rosenberg","year":"2024","unstructured":"Rosenberg V, Amital H, Chodick G, et al. Real-world adherence and drug survival of biologics among patients with ankylosing spondylitis. J Clin Med. 2024;13(15):4480. https:\/\/doi.org\/10.3390\/jcm13154480.","journal-title":"J Clin Med"},{"issue":"9","key":"859_CR48","doi-asserted-by":"publisher","first-page":"997","DOI":"10.18553\/jmcp.2022.28.9.997","volume":"28","author":"A Ogdie","year":"2022","unstructured":"Ogdie A, Hwang M, Veeranki P, et al. Health care utilization and costs associated with functional status in patients with psoriatic arthritis. J Manag Care Spec Pharm. 2022;28(9):997\u20131007. https:\/\/doi.org\/10.18553\/jmcp.2022.28.9.997.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"859_CR49","doi-asserted-by":"publisher","first-page":"157","DOI":"10.20471\/acc.2019.58.01.20","volume":"58","author":"R Martinec","year":"2019","unstructured":"Martinec R, Pinjatela R, Balen D. Quality of life in patients with rheumatoid arthritis\u2014a preliminary study. Acta Clin Croat. 2019;58(1):157\u201366. https:\/\/doi.org\/10.20471\/acc.2019.58.01.20.","journal-title":"Acta Clin Croat"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00859-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00859-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00859-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:17:36Z","timestamp":1785518256000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00859-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["859"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00859-w","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Janet E. Pope has received speaker and advisory board fees from JAK inhibitor companies (Pfizer, Lily, AbbVie, and Gilead Pharmaceuticals). Jayeshkumar Patel, Christopher D. Saffore, Siran Fang, Al Rasymas, and Dalinda Liazoghli are employees of AbbVie and may own stock. Olga Ziouzina has advised and received honoraria or research funding from Amgen, AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Sandoz, and UCB.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical principles that have their origin in the current Declaration of Helsinki and was consistent with International Conference on Harmonization Good Clinical Practice, Good Epidemiology Practices, and applicable regulatory requirements. All participants provided consent to enroll in the upadacitinib AbbVie Care program and for their demographic and clinical information, as well as questionnaire answers, to be used for research purposes. None of the patients analyzed had their identity or medical records disclosed for the purposes of this study, and only anonymized patient-level data were accessed. Because no identifiable protected health information was extracted or accessed during the course of this study, no institutional review board review or approval was required [\n                      \n                      ].","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}